
To: AmeriHealth Caritas Louisiana Providers

Date: September 12, 2022

Subject: Informational Bulletin 22-28: COVID-19 – Commercially Purchased Bebtelovimab Reimbursement (Q0222)

Informational Bulletins that summarize policies and/or procedures are intended for quick reference and are accurate on the date they are issued.

COVID-19 – Commercially Purchased Bebtelovimab Reimbursement (Q0222)

Commercial distribution of the COVID-19 treatment medication Bebtelovimab (Q0222) began on August 15, 2022. This is in addition to a stock of this medication that you may have, that was supplied by the federal government at no cost to you.

Effective for dates of service on or after August 15, 2022, Louisiana Medicaid will require modifier “UC” to identify that the COVID-19 medication administered was commercially purchased. You are to use the same administration codes for both the purchased product and the medication supplied by the federal government.

There are no changes for submitting claims related to the government-supplied medication. If the federal government provided the medication, then no modifier is to be appended and reimbursement is \$0. Seeking reimbursement for the government-provided medication is subject to review, recoupment and further sanctions.

The COVID-19 Vaccine and Treatment fee schedule has been revised to reflect this update. The fee schedule is available on the Medicaid website:

https://www.lamedicaid.com/Provweb1/fee_schedules/COVID-19_Fee.htm

Questions regarding this message should be directed to AmeriHealth Caritas Louisiana Provider Services at 1-888-922-0007. The Provider Services Department can be reached between 7:00 am – 7:00 pm daily.

Missed an Informational Bulletin?

You can find a complete listing of Informational Bulletins on the [Provider Newsletters and Updates](#) page of our website under the header [Louisiana Department of Health Information Bulletins](#).

Need to update your provider information? Send full details to: network@amerihealthcaritasla.com.